SUMMARY Three patients developed peripheral neuropathy after taking amiodarone for more than 18 months. All had high serum concentrations of amiodarone and its desethyl metabolite; in one patient concentrations in a sural nerve biopsy were 80 times higher than in serum. Peripheral neuropathy is a complication of large doses of amiodarone taken over long periods.
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The antiarrhythmic drug amiodarone was first reported as a cause of peripheral neuropathy in 1974. ' 2 Subsequent authors have confirmed this association3 " but they have not explained why particular patients develop this adverse effect. We report three patients who developed peripheral neuropathy while taking amiodarone. Drug concentrations were measured in serum and in one patient also in a peripheral nerve biopsy, and recovery was documented after withdrawal of amiodarone. Similar details have not been reported before. With information from previous reports, some factors can be identified which may be important in the genesis of amiodarone neuropathy. '3 14 gave an amiodarone concentration in the nerve of 187 mg/kg wet weight, and a desethylamiodarone concentration of 203 mg/kg wet weight. At the same time serum concentrations were 2-3 and 2-6 mg/l respectively. Her symptoms started to improve soon after amiodarone was stopped, but no objective improvement was detected until 10 weeks later. After 4 months her paraesthesiae were greatly reduced in severity and muscle power had improved so that she could walk unaided. Knee jerks hlad returned but ankle jerks were still absent. After 9 months she had no sensory symptoms and muscle power was almost normal. Tests of motor nerve conduction confirmed a significant improvement.
Patient 2
This man with coronary artery disease presented in 1980 aged 73 yr with syncope caused by paroxysmal ventricular tachycardia. His arrhythmias were successfully controlled by amiodarone 200 mg daily but recurred after one year. He then took 600 mg daily for more than 2 years, followed by 400 mg daily for 2 months before the drug was discontinued. One year after starting amiodarone he reported a tremor, and 6 months later he reported unsteadiness when walking. Thereafter he developed progressive weakness of his arms and legs, dysaesthesiae in his hands and numbness in his legs. Treatment was continued until November 1983, Peripheral neuropathy during longterm high dose amiodarone therapy Compared with a suggested therapeutic range for amiodarone of 1-0-2-5 mg/l,'5 drug levels in our patients with neuropathy were high. The mean serum concentrations of amiodarone (2.4 mg/l) and desethylamiodarone (3.0 mg/l) were similar to two previous reports (amiodarone [2] [3] [4] and 5-0 mg/l, and desesthylamiodarone 1-7 and 4-0 mg/1'°0"). Concentrations in the sural nerve biopsy were also high (about 80 times greater than in serum) and similar to the previous report of a forty fold increase in iodine content in an affected peripheral nerve.6 Drug concentrations in the sural nerve biopsy from our patient were higher than those found before in many other tissues at necropsy '6 and 
